Lisata Therapeutics, Inc. (NASDAQ:LSTA – Get Free Report)’s stock price shot up 1.4% on Friday . The company traded as high as $2.37 and last traded at $2.14. 25,306 shares changed hands during trading, an increase of 32% from the average session volume of 19,230 shares. The stock had previously closed at $2.11.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Lisata Therapeutics in a research report on Tuesday, August 15th.
Lisata Therapeutics Price Performance
Lisata Therapeutics (NASDAQ:LSTA – Get Free Report) last released its quarterly earnings data on Monday, August 14th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.20. Analysts anticipate that Lisata Therapeutics, Inc. will post -3.27 EPS for the current fiscal year.
Hedge Funds Weigh In On Lisata Therapeutics
Several institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC bought a new position in Lisata Therapeutics during the second quarter valued at $64,000. BML Capital Management LLC purchased a new stake in shares of Lisata Therapeutics in the fourth quarter valued at $617,000. State Street Corp purchased a new stake in shares of Lisata Therapeutics in the third quarter valued at $66,000. Vanguard Group Inc. purchased a new stake in shares of Lisata Therapeutics in the third quarter valued at $817,000. Finally, BlackRock Inc. purchased a new stake in shares of Lisata Therapeutics in the third quarter valued at $263,000. Institutional investors own 8.36% of the company’s stock.
About Lisata Therapeutics
Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 1b/2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; HONEDRA, a recipient of SAKIGAKE designation critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and LSTA201, a CD34+ cell therapy for the treatment of chronic kidney disease.
- Five stocks we like better than Lisata Therapeutics
- Stock Market Sectors: What Are They and How Many Are There?
- The Best 5 Small Cap AI Companies to Buy Now
- How to Build Wealth with the Dividend Aristocrat Index
- Miso Robotics Stock: Is an IPO Coming Soon?
- The Significance of Brokerage Rankings in Stock Selection
- 3 Stocks to Play the Easing Food Supply Chain
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.